27

Amgen names Ray Jordan senior VP Corporate Affairs

pharmafile | September 24, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, J&J, JJ, Ray Jordan 

Amgen has announced the appointment of ex-J&J comms leader Ray Jordan to the new position of senior vice president, Corporate Affairs.

Jordan will report directly to Robert Bradway, president and chief executive, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.

Since 2003 Jordan has served as communications leader at Johnson & Johnson, responsible for corporate communications and public affairs for more than 250 operating companies in 60 countries. 

Advertisement

Prior to joining J&J, Jordan was vice president, communications and information, for Pfizer, where he held a range of positions over the course of 17 years. He also served as chair of PhRMA’s public affairs section and of the National Pharmaceutical Council’s User Group. Earlier in his career, Jordan was a reporter for a regional daily newspaper and held positions with Bristol-Myers and Dun & Bradstreet.

“We are very pleased to have Ray join Amgen,” said Bradway. “He is a strategic thinker and communicator with skills honed at two respected global healthcare companies.  Ray’s background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders.”

Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma

Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …

The Gateway to Local Adoption Series

Latest content